REGistry of Long-term AnTithrombotic TherApy-1

National Medical Research Center for Cardiology, Ministry of Health of Russian Federation2,000 enrolled

Overview

To assess the rates of ischemic and hemorrhagic complications of long-term antithrombotic therapy in patients with chronic coronary syndromes

The register is a Russian prospective single-center observational study of patients who have indications for long-term antithrombotic therapy in connection with chronic coronary syndromes

Study Type

OBSERVATIONAL

Enrollment

2,000

Conditions

Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD))Peripheral Artery Disease

Interventions

Antiplatelet DrugDRUG

single or dual antiplatelets, triple antithrombotic therapy

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * coronary artery disease , confirmed by history of myocardial infarction, or revascularization, or definitive evidence of CAD on imaging Exclusion Criteria: * Subjects who are unwilling or unable to provide informed consent. * Acute coronary syndrome within 12 months before inclusion * Severe chronic heart failure (NYHA IV) * Stroke within 6 months before inclusion * Severe liver or muscle disease * Severe kidney disease / renal failure with creatinine \> 3 mg/dl * Conceivable impossibility to come in touch with the patient or his family at 1-year after the intervention -

Locations (1)

National Medical Research Center for Cardiology, Ministry of Health of Russian Federation

Moscow, Russia

RECRUITING

Outcomes

Primary Outcomes

composite of major adverse cardiovascular events (MACE)

stroke, myocardial infarction, stent thrombosis \[definite or probable\], or urgent revascularization, cardiac death

Time frame: inclusion up to 5 years

composite of any bleeding events

major, clinically relevant nonmajor, minor (BARC, ISTH)

Time frame: inclusion up to 5 years

Secondary Outcomes

Severity of peripheral atherosclerosis

Assessment will be performed with the use of duplex scanning

Time frame: inclusion

Mutations in following genes

CYP2C19\*, ABCB1

Time frame: inclusion

Central Contacts

Andrey Komarov, PhD

CONTACT

+79161813257 andrkomarov@mail.ru

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.